Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Rinvoq for ulcerative colitis?Tadalafil patent expiration?When does clinuvel pharmacy run out of fda patent protection for scenesse?Etodolac lodine manufacturing plant cost?When there was humalog insulin loss of exclusivity in european?
See the DrugPatentWatch profile for Neupro
Who owns Neupro? Neupro is an implantable transdermal patch developed by Schwartz Pharma (now part of UCB) for the treatment of Parkinson's disease, restless legs syndrome, and major depressive disorder [1]. The company behind Neupro is UCB, a global biopharmaceutical company headquartered in Belgium. UCB's pipeline and focus UCB has a diverse pipeline of treatments for various conditions, including neurology, autoimmune, and cancer. In neurology, Neupro is one of the company's key assets, alongside other treatments like Vimpat (lacosamide) for epilepsy and epilepsy-related seizures [2]. Neupro's unique features and mechanism Neupro contains rotigotine, a dopamine agonist that is absorbed through the skin into the bloodstream. This allows for prolonged and targeted delivery of the medication, providing symptom relief for up to 24 hours [3]. Neupro is available in various doses, from 4 to 30 mg, and the dosing needs to be adjusted by a healthcare professional. Pricing and competition The cost of Neupro can vary depending on the country, doctor's prescription, and insurance. According to Drugs.com, the prices for Neupro patches range from $150 to $200 for a 30-day supply, depending on the strength and dosage [4]. While not the cheapest option, Neupro is considered a valuable treatment for patients who struggle with swallowing or have difficulty managing oral medications. Patent status and exclusivity As of my knowledge cutoff in 2023, the original patents for Neupro's technology expired, but UCB has filed additional patents to extend its exclusivity and protect its market position [5]. It's essential to consult DrugPatentWatch.com for up-to-date information on patent status, expiration dates, and exclusivity periods. References [1] UCB Group. (n.d.). Neupro. Retrieved from https://www.ucb.com/en/patients/our-medicines/neupro [2] UCB Group. (n.d.). Pipeline. Retrieved from https://www.ucb.com/en/pipeline [3] Schwartz Pharma. (n.d.). Rotigotine (Neupro). Retrieved from https://www.rotigotine.com/ [4] Drugs.com. (n.d.). Neupro Prices, Coupons and Patient Assistance Programs. Retrieved from https://www.drugs.com/price-guide/neupro [5] DrugPatentWatch.com. (n.d.). Neupro. Retrieved from https://www.drugpatentwatch.com/drug/neupro
Other Questions About Neupro :